CoChat

Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy

Open access
Ferrari, Samuele, Valeri, Erika, Conti, Anastasia, Scala, Serena, Aprile, Annamaria, Di Micco, Raffaella, Kajaste-Rudnitski, Anna, Montini, Eugenio, Ferrari, Giuliana, Aiuti, Alessandro, Naldini, Luigi · 2023 · Cell Stem Cell
Cited by 70

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Abstract

The growing clinical success of hematopoietic stem/progenitor cell (HSPC) gene therapy (GT) relies on the development of viral vectors as portable "Trojan horses" for safe and efficient gene transfer. The recent advent of novel technologies enabling site-specific gene editing is broadening the scope and means of GT, paving the way to more precise genetic engineering and expanding the spectrum of diseases amenable to HSPC-GT. Here, we provide an overview of state-of-the-art and prospective developments of the HSPC-GT field, highlighting how advances in biological characterization and manipulation of HSPCs will enable the design of the next generation of these transforming therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.stem.2023.04.014

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 204

  1. Ferrari, 2021, Gene therapy using haematopoietic stem and progenitor cells, Nat. Rev. Genet., 22, 216, 10.1038/s41576-020-00298-5 · DOI · Paper page
  2. Aiuti, 2002, Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning, Science, 10.1126/science.1070104 · DOI · Paper page
  3. Cavazzana-Calvo, 2000, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, Science, 288, 669, 10.1126/science.288.5466.669 · DOI · Paper page
  4. Hacein-Bey-Abina, 2002, Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy, N. Engl. J. Med., 346, 1185, 10.1056/NEJMoa012616 · DOI · Paper page
  5. Gaspar, 2004, Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector, Lancet, 364, 2181, 10.1016/S0140-6736(04)17590-9 · DOI · Paper page
  6. Hacein-Bey-Abina, 2003, LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 · DOI · Paper page
  7. Naldini, 2016, Lentiviral vectors, two decades later, Science, 353, 1101, 10.1126/science.aah6192 · DOI · Paper page
  8. Kohn, 2021, Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency, N. Engl. J. Med., 384, 2002, 10.1056/NEJMoa2027675 · DOI · Paper page
  9. Cicalese, 2018, Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety, Mol. Ther., 26, 917, 10.1016/j.ymthe.2017.12.022 · DOI
  10. de Ravin, 2016, Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency, Sci. Transl. Med., 8, 10.1126/scitranslmed.aad8856 · DOI · Paper page
  11. Magnani, 2022, Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome, Nat. Med., 28, 71, 10.1038/s41591-021-01641-x · DOI · Paper page
  12. Ferrua, 2019, Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study, Lancet. Haematol., 6, 10.1016/S2352-3026(19)30021-3 · DOI · Paper page
  13. Kohn, 2020, Lentiviral gene therapy for X-linked chronic granulomatous disease., Nat Med, 26, 200, 10.1038/s41591-019-0735-5 · DOI · Paper page
  14. Gentner, 2021, Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome, N. Engl. J. Med., 385, 1929, 10.1056/NEJMoa2106596 · DOI · Paper page
  15. Marktel, 2019, Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia, Nat. Med., 25, 234, 10.1038/s41591-018-0301-6 · DOI · Paper page
  16. Locatelli, 2022, Betibeglogene Autotemcel Gene Therapy for Non–β 0/β 0 Genotype β-Thalassemia, N. Engl. J. Med., 386, 415, 10.1056/NEJMoa2113206 · DOI · Paper page
  17. Río, 2019, Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia, Nat. Med., 25, 1396, 10.1038/s41591-019-0550-z · DOI · Paper page
  18. Tucci, 2022, A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders, Nat. Commun., 13, 10.1038/s41467-022-28762-2 · DOI · Paper page
  19. Czechowicz, 2019, Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation, Nat. Commun., 10, 10.1038/s41467-018-08201-x · DOI · Paper page
  20. Kwon, 2019, Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice, Blood, 133, 2104, 10.1182/blood-2018-06-853879 · DOI · Paper page
  21. Palchaudhuri, 2016, Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin, Nat. Biotechnol., 34, 738, 10.1038/nbt.3584 · DOI · Paper page
  22. Biffi, 2013, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy, Science, 341, 10.1126/science.1233158 · DOI · Paper page
  23. Peviani, 2023, An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model., EMBO Mol. Med., 10.15252/emmm.202215968 · DOI
  24. Birocchi, 2022, Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models, Sci. Transl. Med., 14, 4106, 10.1126/scitranslmed.abl4106 · DOI
  25. Mucci, 2021, Myeloid cell-based delivery of IFN-γ reprograms the leukemia microenvironment and induces anti-tumoral immune responses, EMBO Mol. Med., 13, 10.15252/emmm.202013598 · DOI
  26. Escobar, 2018, Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens, Nat. Commun., 9, 10.1038/s41467-018-05315-0 · DOI
  27. Craigie, 2014, Host Factors in Retroviral Integration and the Selection of Integration Target Sites, Microbiol. Spectr., 2, 10.1128/microbiolspec.MDNA3-0026-2014 · DOI · Paper page
  28. Hacein-Bey Abina, 2015, Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome, JAMA, 313, 1550, 10.1001/jama.2015.3253 · DOI · Paper page
  29. Cesana, 2021, Retrieval of vector integration sites from cell-free DNA, Nat. Med., 27, 1458, 10.1038/s41591-021-01389-4 · DOI · Paper page
  30. Six, 2020, Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs, Blood, 135, 1219, 10.1182/blood.2019002350 · DOI · Paper page
  31. Scala, 2018, Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans, Nat. Med., 24, 1683, 10.1038/s41591-018-0195-3 · DOI · Paper page
  32. Scala, 2019, In vivo dynamics of human hematopoietic stem cells: novel concepts and future directions, Blood Adv., 3, 1916, 10.1182/bloodadvances.2019000039 · DOI · Paper page
  33. Kebriaei, 2017, Gene Therapy with the Sleeping Beauty Transposon System, Trends Genet., 33, 852, 10.1016/j.tig.2017.08.008 · DOI
  34. Tipanee, 2017, Preclinical and clinical advances in transposon-based gene therapy, Biosci. Rep., 37, 10.1042/BSR20160614 · DOI · Paper page
  35. Moretti, 2022, The Past, Present, and Future of Non-Viral CAR T Cells, Front. Immunol., 13, 867013, 10.3389/fimmu.2022.867013 · DOI
  36. Scully, 2019, DNA double-strand break repair-pathway choice in somatic mammalian cells, Nat. Rev. Mol. Cell Biol., 20, 698, 10.1038/s41580-019-0152-0 · DOI · Paper page
  37. Shy, 2022, High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails, Nat. Biotechnol., 2022, 1
  38. Pattabhi, 2019, Vivo Outcome of Homology-Directed Repair at the HBB Gene in HSC Using Alternative Donor Template Delivery Methods, Mol. Ther. Nucleic Acids, 17, 277, 10.1016/j.omtn.2019.05.025 · DOI · Paper page
  39. Romero, 2019, Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates, Mol. Ther., 27, 1389, 10.1016/j.ymthe.2019.05.014 · DOI · Paper page
  40. Ferrari, 2020, Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking, Nat. Biotechnol., 38, 1298, 10.1038/s41587-020-0551-y · DOI · Paper page
  41. Demirci, 2020, BCL11A enhancer–edited hematopoietic stem cells persist in rhesus monkeys without toxicity, J. Clin. Invest., 130, 6677, 10.1172/JCI140189 · DOI · Paper page
  42. Charlesworth, 2018, Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting, Mol. Ther. Nucleic Acids, 12, 89, 10.1016/j.omtn.2018.04.017 · DOI
  43. Lattanzi, 2021, Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease, Sci. Transl. Med., 13, 10.1126/scitranslmed.abf2444 · DOI · Paper page
  44. Lomova, 2019, Improving Gene Editing Outcomes in Human Hematopoietic Stem and Progenitor Cells by Temporal Control of DNA Repair, Stem Cell., 37, 284, 10.1002/stem.2935 · DOI · Paper page
  45. Shin, 2020, Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor Cells, Cell Rep., 32, 10.1016/j.celrep.2020.108093 · DOI
  46. Canny, 2018, Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR–Cas9 genome-editing efficiency, Nat. Biotechnol., 36, 95, 10.1038/nbt.4021 · DOI · Paper page
  47. Rai, 2020, Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome, Nat. Commun., 11, 10.1038/s41467-020-17626-2 · DOI · Paper page
  48. Nguyen, 2020, Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency, Nat. Biotechnol., 38, 44, 10.1038/s41587-019-0325-6 · DOI · Paper page
  49. Chen, 2021, Enhanced prime editing systems by manipulating cellular determinants of editing outcomes, Cell, 184, 5635, 10.1016/j.cell.2021.09.018 · DOI · Paper page
  50. Ferreira da Silva, 2022, Prime editing efficiency and fidelity are enhanced in the absence of mismatch repair, Nat. Commun., 13, 10.1038/s41467-022-28442-1 · DOI · Paper page
  51. Yarnall, 2022, Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases, Nat. Biotechnol., 41, 500, 10.1038/s41587-022-01527-4 · DOI · Paper page
  52. Anzalone, 2022, Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing, Nat. Biotechnol., 40, 731, 10.1038/s41587-021-01133-w · DOI · Paper page
  53. Jiang, 2022, Deletion and replacement of long genomic sequences using prime editing, Nat. Biotechnol., 40, 227, 10.1038/s41587-021-01026-y · DOI · Paper page
  54. Wang, 2022, Efficient targeted insertion of large DNA fragments without DNA donors, Nat. Methods, 19, 331, 10.1038/s41592-022-01399-1 · DOI · Paper page
  55. Newby, 2021, Base editing of haematopoietic stem cells rescues sickle cell disease in mice, Nature, 595, 295, 10.1038/s41586-021-03609-w · DOI · Paper page
  56. Siegner, 2022, Adenine base editing efficiently restores the function of Fanconi anemia hematopoietic stem and progenitor cells, Nat. Commun., 13, 10.1038/s41467-022-34479-z · DOI
  57. Hardouin, 2022, Adenine base editor-mediated correction of the common and severe IVS1–110 (G>A) β-thalassemia mutation, Blood, 141, 1169, 10.1182/blood.2022016629 · DOI
  58. Antoniou, 2022, Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression, Nat. Commun., 13, 10.1038/s41467-022-34493-1 · DOI
  59. Zeng, 2020, Therapeutic base editing of human hematopoietic stem cells, Nat. Med., 26, 535, 10.1038/s41591-020-0790-y · DOI · Paper page
  60. Li, 2023, In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model, Blood
  61. Zetsche, 2015, Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System, Cell, 163, 759, 10.1016/j.cell.2015.09.038 · DOI · Paper page
  62. Strecker, 2019, RNA-guided DNA insertion with CRISPR-associated transposases, Science, 365, 48, 10.1126/science.aax9181 · DOI · Paper page
  63. Pallarès-Masmitjà, 2021, Find and cut-and-transfer (FiCAT) mammalian genome engineering, Nat. Commun., 12, 7071, 10.1038/s41467-021-27183-x · DOI
  64. Tou, 2023, Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases, Nat. Biotechnol, 10.1038/s41587-022-01574-x · DOI
  65. El-Kharrag, 2022, Efficient polymer nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells, Mol. Ther., 30, 2186, 10.1016/j.ymthe.2022.02.026 · DOI
  66. Mitchell, 2022, Clonal dynamics of haematopoiesis across the human lifespan, Nature, 606, 343, 10.1038/s41586-022-04786-y · DOI · Paper page
  67. Cull, 2021, Clonal Tracking By Whole Genome Sequencing Permits Comprehensive Mapping of the Genomic Landscape in Pre- and Post-Gene Therapy Sickle Cell Patients, Blood, 138, 10.1182/blood-2021-152262 · DOI
  68. Arumugam, 2009, Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region, Mol. Ther., 17, 1929, 10.1038/mt.2009.183 · DOI · Paper page
  69. Schwarzer, 2021, Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning, Mol. Ther., 29, 3383, 10.1016/j.ymthe.2021.06.017 · DOI
  70. Modlich, 2006, Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity, Blood, 108, 2545, 10.1182/blood-2005-08-024976 · DOI · Paper page
  71. Montini, 2006, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration, Nat. Biotechnol., 24, 687, 10.1038/nbt1216 · DOI · Paper page
  72. Cesana, 2012, Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations, J. Clin. Invest., 122, 1667, 10.1172/JCI62189 · DOI · Paper page
  73. Moiani, 2012, Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts, J. Clin. Invest., 122, 1653, 10.1172/JCI61852 · DOI · Paper page
  74. Scholz, 2017, Lentiviral Vector Promoter is Decisive for Aberrant Transcript Formation, Hum. Gene Ther., 28, 875, 10.1089/hum.2017.162 · DOI
  75. de Ravin, 2022, Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency, Nat. Commun., 13, 3710, 10.1038/s41467-022-31344-x · DOI · Paper page
  76. Servick, 2021, Gene therapy clinical trial halted as cancer risk surfaces, Science
  77. 2022, 2022 ASGCT Annual Meeting Abstracts, Mol. Ther., 30, 1
  78. Biavasco, 2021, Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis, Nat. Commun., 12, 10.1038/s41467-021-24876-1 · DOI · Paper page
  79. Nelson, 2019, Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy, Nat. Med., 25, 427, 10.1038/s41591-019-0344-3 · DOI · Paper page
  80. Tsai, 2016, Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases, Nat. Rev. Genet., 17, 300, 10.1038/nrg.2016.28 · DOI · Paper page
  81. Clement, 2020, Technologies and Computational Analysis Strategies for CRISPR Applications, Mol. Cell, 79, 11, 10.1016/j.molcel.2020.06.012 · DOI
  82. AlJanahi, 2022, Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques, Mol. Ther., 30, 209, 10.1016/j.ymthe.2021.06.016 · DOI
  83. Chung, 2020, Computational Analysis Concerning the Impact of DNA Accessibility on CRISPR-Cas9 Cleavage Efficiency, Mol. Ther., 28, 19, 10.1016/j.ymthe.2019.10.008 · DOI · Paper page
  84. Petri, 2021, Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects, bioRxiv
  85. Cancellieri, 2023, Human genetic diversity alters off-target outcomes of therapeutic gene editing, Nat. Genet., 55, 34, 10.1038/s41588-022-01257-y · DOI
  86. Weisheit, 2021, Simple and reliable detection of CRISPR-induced on-target effects by qgPCR and SNP genotyping, Nat. Protoc., 16, 1714, 10.1038/s41596-020-00481-2 · DOI
  87. Park, 2022, Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing, Sci Adv, 8, 10.1126/sciadv.abo7676 · DOI · Paper page
  88. Nahmad, 2022, Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage, Nat. Biotechnol., 40, 1807, 10.1038/s41587-022-01377-0 · DOI · Paper page
  89. Turchiano, 2021, Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq, Cell Stem Cell, 28, 1136, 10.1016/j.stem.2021.02.002 · DOI · Paper page
  90. Amendola, 2022, CRISPRthripsis: The Risk of CRISPR/Cas9-induced Chromothripsis in Gene Therapy, Stem Cells Transl. Med., 11, 1003, 10.1093/stcltm/szac064 · DOI
  91. Colella, 2018, Emerging Issues in AAV-Mediated In Vivo Gene Therapy, Mol. Ther. Methods Clin. Dev., 8, 87, 10.1016/j.omtm.2017.11.007 · DOI · Paper page
  92. Dalwadi, 2021, AAV integration in human hepatocytes, Mol. Ther., 29, 2898, 10.1016/j.ymthe.2021.08.031 · DOI · Paper page
  93. Nguyen, 2021, A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells, Nat. Biotechnol., 39, 47, 10.1038/s41587-020-0741-7 · DOI · Paper page
  94. Chandler, 2017, Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models, Hum. Gene Ther., 28, 314, 10.1089/hum.2017.009 · DOI · Paper page
  95. Jeong, 2020, Current Status and Challenges of DNA Base Editing Tools, Mol. Ther., 28, 1938, 10.1016/j.ymthe.2020.07.021 · DOI
  96. Rees, 2019, Analysis and minimization of cellular RNA editing by DNA adenine base editors, Sci. Adv., 5, 10.1126/sciadv.aax5717 · DOI · Paper page
  97. Gaudelli, 2020, Directed evolution of adenine base editors with increased activity and therapeutic application, Nat. Biotechnol., 38, 892, 10.1038/s41587-020-0491-6 · DOI · Paper page
  98. Renouf, 2014, Creating cancer translocations in human cells using Cas9 DSBs and nCas9 paired nicks, Methods Enzymol., 546, 251, 10.1016/B978-0-12-801185-0.00012-X · DOI
  99. Bothmer, 2017, Characterization of the interplay between DNA repair and CRISPR/Cas9-induced DNA lesions at an endogenous locus, Nat. Commun., 8, 13905, 10.1038/ncomms13905 · DOI · Paper page
  100. Tao, 2022, Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites, Nat. Commun., 13, 10.1038/s41467-022-31322-3 · DOI
  101. Levesque, 2022, Marker-free co-selection for successive rounds of prime editing in human cells, Nat. Commun., 13, 10.1038/s41467-022-33669-z · DOI
  102. Lovell-Badge, 2021, ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update, Stem Cell Rep., 16, 1398, 10.1016/j.stemcr.2021.05.012 · DOI · Paper page
  103. Sharma, 2021, The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells, Nat. Commun., 12, 10.1038/s41467-020-20792-y · DOI
  104. Ferrari, 2021, BAR-Seq clonal tracking of gene-edited cells, Nat. Protoc., 16, 2991, 10.1038/s41596-021-00529-x · DOI
  105. Ludwig, 2019, Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics, Cell, 176, 1325, 10.1016/j.cell.2019.01.022 · DOI · Paper page
  106. Uchida, 2021, Preclinical evaluation for engraftment of CD34 + cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models Demonstrate engraftment of gene-edited CD34 + cells in xenografts and non-human primates., Cell Rep Med, 2
  107. Ngom, 2018, UM171 Enhances Lentiviral Gene Transfer and Recovery of Primitive Human Hematopoietic Cells, Mol. Ther. Methods Clin. Dev., 10, 156, 10.1016/j.omtm.2018.06.009 · DOI
  108. Zonari, 2017, Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy, Stem Cell Rep., 8, 977, 10.1016/j.stemcr.2017.02.010 · DOI · Paper page
  109. Naldini, 2019, Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives, EMBO Mol. Med., 11, 10.15252/emmm.201809958 · DOI · Paper page
  110. Boitano, 2010, Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells, Science, 329, 1345, 10.1126/science.1191536 · DOI · Paper page
  111. Jackson, 2017, Targeting the aryl hydrocarbon receptor nuclear translocator complex with DMOG and Stemregenin 1 improves primitive hematopoietic stem cell expansion, Stem Cell Res., 21, 124, 10.1016/j.scr.2017.04.007 · DOI
  112. Casado, 2016, The Aryl Hydrocarbon Receptor Relays Metabolic Signals to Promote Cellular Regeneration, Stem Cells Int., 2016, 10.1155/2016/4389802 · DOI
  113. Fares, 2014, Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal, Science, 345, 1509, 10.1126/science.1256337 · DOI · Paper page
  114. Fares, 2017, EPCR expression marks UM171-expanded CD34+ cord blood stem cells, Blood, 129, 3344, 10.1182/blood-2016-11-750729 · DOI · Paper page
  115. Hoggatt, 2009, Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation, Blood, 113, 5444, 10.1182/blood-2009-01-201335 · DOI · Paper page
  116. Watts, 2011, Hematopoietic stem cell expansion and gene therapy, Cytotherapy, 13, 1164, 10.3109/14653249.2011.620748 · DOI
  117. Cutler, 2013, Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation, Blood, 122, 3074, 10.1182/blood-2013-05-503177 · DOI · Paper page
  118. Horwitz, 2014, Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment, J. Clin. Invest., 124, 3121, 10.1172/JCI74556 · DOI · Paper page
  119. Piras, 2017, Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells, EMBO Mol. Med., 9, 1198, 10.15252/emmm.201707922 · DOI · Paper page
  120. Mazurier, 2004, Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment, Blood, 103, 545, 10.1182/blood-2003-05-1558 · DOI · Paper page
  121. Walter, 2015, Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells, Nature, 520, 549, 10.1038/nature14131 · DOI · Paper page
  122. Ahuja, 2016, A short G1 phase imposes constitutive replication stress and fork remodelling in mouse embryonic stem cells, Nat. Commun., 7, 10.1038/ncomms10660 · DOI · Paper page
  123. Horn, 2002, Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons, Gene Ther., 9, 1464, 10.1038/sj.gt.3301820 · DOI
  124. Jang, 2007, A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche, Blood, 110, 3056, 10.1182/blood-2007-05-087759 · DOI · Paper page
  125. Yahata, 2011, Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells, Blood, 118, 2941, 10.1182/blood-2011-01-330050 · DOI · Paper page
  126. Morganti, 2022, Metabolic Regulation of Hematopoietic Stem Cells, Hemasphere, 6, 10.1097/HS9.0000000000000740 · DOI
  127. Farlik, 2016, DNA Methylation Dynamics of Human Hematopoietic Stem Cell Differentiation, Cell Stem Cell, 19, 808, 10.1016/j.stem.2016.10.019 · DOI · Paper page
  128. Dircio-Maldonado, 2018, Functional Integrity and Gene Expression Profiles of Human Cord Blood-Derived Hematopoietic Stem and Progenitor Cells Generated In Vitro., Stem Cells Transl. Med., 7, 602, 10.1002/sctm.18-0013 · doi:10.1002/sctm.18-0013
  129. McDermott, 2015, Chromothriptic Cure of WHIM Syndrome, Cell, 160, 686, 10.1016/j.cell.2015.01.014 · DOI · Paper page
  130. Hou, 2021, Somatic Reversion of a Novel IL2RG Mutation Resulting in Atypical X-Linked Combined Immunodeficiency, Genes, 13, 10.3390/genes13010035 · DOI
  131. Waisfisz, 1999, Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism, Nat. Genet., 22, 379, 10.1038/11956 · DOI · Paper page
  132. Miyazawa, 2021, Reversion Mosaicism in Primary Immunodeficiency Diseases, Front. Immunol., 12, 10.3389/fimmu.2021.783022 · DOI
  133. Blümich, 2021, Human CD34+ Hematopoietic Stem Cell-Engrafted NSG Mice: Morphological and Immunophenotypic Features, Vet. Pathol., 58, 161, 10.1177/0300985820948822 · DOI
  134. Kamel-Reid, 1988, Engraftment of immune-deficient mice with human hematopoietic stem cells, Science, 242, 1706, 10.1126/science.2904703 · DOI · Paper page
  135. Aryee, 2014, Immunodeficient mouse model for human hematopoietic stem cell engraftment and immune system development, Methods Mol. Biol., 1185, 267, 10.1007/978-1-4939-1133-2_18 · DOI
  136. Walsh, 2017, Humanized Mouse Models of Clinical Disease, Annu. Rev. Pathol., 12, 187, 10.1146/annurev-pathol-052016-100332 · DOI · Paper page
  137. Wen, 2021, Single-cell RNA sequencing reveals the landscapes of human cord blood hematopoietic stem cell differentiation during ex vivo culture, Clin. Transl. Med., 11, 10.1002/ctm2.616 · doi:10.1002/ctm2.616
  138. Mende, 2022, Unique molecular and functional features of extramedullary hematopoietic stem and progenitor cell reservoirs in humans, Blood, 139, 3387, 10.1182/blood.2021013450 · DOI
  139. Belluschi, 2018, Myelo-lymphoid lineage restriction occurs in the human haematopoietic stem cell compartment before lymphoid-primed multipotent progenitors, Nat. Commun., 9, 10.1038/s41467-018-06442-4 · DOI · Paper page
  140. Calvanese, 2022, Mapping human haematopoietic stem cells from haemogenic endothelium to birth, Nature, 604, 534, 10.1038/s41586-022-04571-x · DOI · Paper page
  141. Calvanese, 2019, MLLT3 governs human haematopoietic stem-cell self-renewal and engraftment, Nature, 576, 281, 10.1038/s41586-019-1790-2 · DOI · Paper page
  142. Luff, 2022, Identification of a retinoic acid-dependent haemogenic endothelial progenitor from human pluripotent stem cells, Nat. Cell Biol., 24, 616, 10.1038/s41556-022-00898-9 · DOI
  143. Ditadi, 2017, A view of human haematopoietic development from the Petri dish, Nat. Rev. Mol. Cell Biol., 18, 56, 10.1038/nrm.2016.127 · DOI · Paper page
  144. Ivanovs, 2017, Human haematopoietic stem cell development: from the embryo to the dish, Development, 144, 2323, 10.1242/dev.134866 · DOI · Paper page
  145. Capo, 2021, Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis, Haematologica, 106, 74, 10.3324/haematol.2019.238261 · DOI
  146. Sakurai, 2023, Chemically defined cytokine-free expansion of human haematopoietic stem cells, Nature, 615, 127, 10.1038/s41586-023-05739-9 · DOI · Paper page
  147. Bai, 2019, Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel, Nat. Med., 25, 1566, 10.1038/s41591-019-0601-5 · DOI · Paper page
  148. Piras, 2021, Antiviral immunity and nucleic acid sensing in haematopoietic stem cell gene engineering, Gene Ther., 28, 16, 10.1038/s41434-020-0175-3 · DOI
  149. Rehwinkel, 2020, RIG-I-like receptors: their regulation and roles in RNA sensing, Nat. Rev. Immunol., 20, 537, 10.1038/s41577-020-0288-3 · DOI · Paper page
  150. Decout, 2021, The cGAS-STING pathway as a therapeutic target in inflammatory diseases, Nat. Rev. Immunol., 21, 548, 10.1038/s41577-021-00524-z · DOI · Paper page
  151. Sumner, 2020, Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA, EMBO J., 39, 10.15252/embj.2019103958 · DOI
  152. Wienert, 2018, In vitro-transcribed guide RNAs trigger an innate immune response via the RIG-I pathway, PLoS Biol., 16, 10.1371/journal.pbio.2005840 · DOI · Paper page
  153. Wu, 2018, Intrinsic Immunity Shapes Viral Resistance of Stem Cells, Cell, 172, 423, 10.1016/j.cell.2017.11.018 · DOI · Paper page
  154. Petrillo, 2018, Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells, Cell Stem Cell, 23, 820, 10.1016/j.stem.2018.10.008 · DOI · Paper page
  155. Shi, 2018, mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3, Proc. Natl. Acad. Sci. USA, 115, E10069, 10.1073/pnas.1811892115 · DOI
  156. Ozog, 2019, Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes, Blood, 134, 1298, 10.1182/blood.2019000040 · DOI
  157. Heffner, 2018, Prostaglandin E2 Increases Lentiviral Vector Transduction Efficiency of Adult Human Hematopoietic Stem and Progenitor Cells, Mol. Ther., 26, 320, 10.1016/j.ymthe.2017.09.025 · DOI · Paper page
  158. Masiuk, 2019, PGE2 and Poloxamer Synperonic F108 Enhance Transduction of Human HSPCs with a β-Globin Lentiviral Vector, Mol. Ther. Methods Clin. Dev., 13, 390, 10.1016/j.omtm.2019.03.005 · DOI
  159. Evans, 2014, TRIM5α variations influence transduction efficiency with lentiviral vectors in both human and rhesus CD34(+) cells in vitro and in vivo, Mol. Ther., 22, 348, 10.1038/mt.2013.256 · DOI
  160. Cavazzana, 2017, Gene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow’s Point of View, Stem Cells Dev., 26, 71, 10.1089/scd.2016.0230 · DOI
  161. Canarutto, 2021, Peripheral blood stem and progenitor cell collection in pediatric candidates for ex vivo gene therapy: a 10-year series, Mol. Ther. Methods Clin. Dev., 22, 76, 10.1016/j.omtm.2021.05.013 · DOI
  162. Körbling, 2001, Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?, Blood, 98, 2900, 10.1182/blood.V98.10.2900 · DOI · Paper page
  163. Scala, 2021, Haematopoietic reconstitution dynamics of mobilized peripheral blood-and bone marrow-derived haematopoietic stem/progenitor cells after gene therapy, Hum Gene Ther, 23
  164. Steidl, 2002, Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells, Blood, 99, 2037, 10.1182/blood.V99.6.2037 · DOI · Paper page
  165. Thornley, 2001, Differences in cell cycle kinetics of candidate engrafting cells in human bone marrow and mobilized peripheral blood, Exp. Hematol., 29, 525, 10.1016/S0301-472X(00)00683-4 · doi:10.1016/s0301-472x(00)00683-4
  166. Donahue, 1996, Peripheral Blood CD34+ Cells Differ From Bone Marrow CD34+ Cells in Thy-1 Expression and Cell Cycle Status in Nonhuman Primates Mobilized or Not Mobilized With Granulocyte Colony-Stimulating Factor and/or Stem Cell Factor, Blood, 87, 1644, 10.1182/blood.V87.4.1644.bloodjournal8741644 · DOI
  167. Sereni, 2018, Autonomous role of Wiskott-Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation, J. Allergy Clin. Immunol., 142, 1272, 10.1016/j.jaci.2017.12.1000 · DOI
  168. Wilkinson, 2021, Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice, Nat. Commun., 12, 10.1038/s41467-021-20909-x · DOI
  169. Miccio, 2008, In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia, Proc. Natl. Acad. Sci. USA, 105, 10547, 10.1073/pnas.0711666105 · DOI · Paper page
  170. Ramírez, 2021, Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients, Am. J. Hematol., 96, 989, 10.1002/ajh.26234 · doi:10.1002/ajh.26234
  171. Gentner, 2019, Vivo Selection for Gene-Corrected HSPCs Advances Gene Therapy for a Rare Stem Cell Disease, Cell Stem Cell, 25, 592, 10.1016/j.stem.2019.10.004 · DOI
  172. Aprile, 2020, Hematopoietic stem cell function in β-thalassemia is impaired and is rescued by targeting the bone marrow niche, Blood, 136, 610, 10.1182/blood.2019002721 · DOI
  173. Tang, 2021, Murine bone marrow mesenchymal stromal cells have reduced hematopoietic maintenance ability in sickle cell disease, Blood, 138, 2570, 10.1182/blood.2021012663 · DOI
  174. Crippa, 2019, Bone marrow stromal cells from β-thalassemia patients have impaired hematopoietic supportive capacity, J. Clin. Invest., 129, 1566, 10.1172/JCI123191 · DOI
  175. Aprile, 2022, Targeting the Hematopoietic Stem Cell Niche in β-Thalassemia and Sickle Cell Disease, Pharmaceuticals, 15, 10.3390/ph15050592 · DOI
  176. Park, 2020, Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion, Blood, 135, 2071, 10.1182/blood.2019002227 · DOI
  177. Dalle Carbonare, 2015, Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease, Blood, 126, 2320, 10.1182/blood-2015-04-641969 · DOI
  178. Catucci, 2014, Wiskott–Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity, Eur. J. Immunol., 44, 1039, 10.1002/eji.201343935 · DOI
  179. Yuan, 2022, Wiskott-Aldrich syndrome protein forms nuclear condensates and regulates alternative splicing, Nat. Commun., 13
  180. Goyal, 2022, Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease, N. Engl. J. Med., 386, 138, 10.1056/NEJMoa2109167 · DOI · Paper page
  181. Philippidis, 2021, After Analysis, Bluebird Bio Says Vector “Very Unlikely” Cause of Acute Myeloid Leukemia, Hum. Gene Ther., 32, 332, 10.1089/hum.2021.29159.bfs · doi:10.1089/hum.2021.29159.bfs
  182. Kanter, 2023, Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study, Am. J. Hematol., 98, 11, 10.1002/ajh.26741 · DOI · Paper page
  183. Jones, 2021, Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither, Blood, 138, 942, 10.1182/blood.2021011488 · DOI · Paper page
  184. Seminog, 2016, Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study, J. R. Soc. Med., 109, 303, 10.1177/0141076816651037 · DOI · Paper page
  185. Brunson, 2017, Increased risk of leukemia among sickle cell disease patients in California, Blood, 130, 1597, 10.1182/blood-2017-05-783233 · DOI · Paper page
  186. Bernardo, 2016, The Role of Conditioning in Hematopoietic Stem-Cell Gene Therapy, Hum Gene Ther, 10.1089/hum.2016.103 · DOI
  187. Charlesworth, 2022, Immunological barriers to haematopoietic stem cell gene therapy, Nat. Rev. Immunol., 22, 719, 10.1038/s41577-022-00698-0 · DOI
  188. Fumagalli, 2022, Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access, Lancet, 399, 372, 10.1016/S0140-6736(21)02017-1 · DOI · Paper page
  189. George, 2019, Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance, Cell Stem Cell, 25, 185, 10.1016/j.stem.2019.05.018 · DOI
  190. Chhabra, 2016, Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy, Sci. Transl. Med., 8, 10.1126/scitranslmed.aae0501 · DOI · Paper page
  191. Griffin, 2022, Worked to the bone: antibody-based conditioning as the future of transplant biology, J. Hematol. Oncol., 15
  192. Ghannam, 2020, Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation, Blood, 135, 1185
  193. Agarwal, 2021, JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID), Blood, 138, 554, 10.1182/blood-2021-153074 · doi:10.1182/blood-2021-153074
  194. Pearse, 2019, A CD117-Amanitin Antibody Drug Conjugate (ADC) Effectively Depletes Human and Non-Human Primate Hematopoietic Stem and Progenitor Cells (HSPCs): targeted Non-Genotoxic Conditioning for Bone Marrow Transplant, Biol. Blood Marrow Transplant., 25, S29, 10.1016/j.bbmt.2018.12.101 · doi:10.1016/j.bbmt.2018.12.101
  195. Omer-Javed, 2022, Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells, Cell, 185, 2248, 10.1016/j.cell.2022.04.039 · DOI
  196. Wang, 2022, In vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4, Blood Adv., 6, 4360, 10.1182/bloodadvances.2022007975 · DOI
  197. Felker, 2022, Differential CXCR4 expression on hematopoietic progenitor cells versus stem cells directs homing and engraftment, JCI Insight, 7, 10.1172/jci.insight.151847 · DOI
  198. Bessy, 2021, Bioengineering the Bone Marrow Vascular Niche, Front. Cell Dev. Biol., 9, 10.3389/fcell.2021.645496 · DOI
  199. Chen, 2022, Live-seq enables temporal transcriptomic recording of single cells, Nature, 608, 733, 10.1038/s41586-022-05046-9 · DOI · Paper page
  200. Hoersten, 2022, Pairing of single mutations yields obligate Cre-type site-specific recombinases, Nucleic Acids Res., 50, 1174, 10.1093/nar/gkab1240 · DOI

200 of 204 shown

Cited by

See all 70

Metadata

Authors
Ferrari, S., Valeri, E., Conti, A., Scala, S., Aprile, A., Di Micco, R., Kajaste-Rudnitski, A., Montini, E., Ferrari, G., Aiuti, A., & Naldini, L.
Venue
Cell Stem Cell
Publisher
Elsevier BV
Published
2023-05
Volume
30
Issue
5
Pages
549-570
ISSN
  • 1875-9777 (ISSN-L)
  • 1934-5909
OpenAlex
W4368363424
Cited by
70
References
73
FWCI
10.25
Type
journal article
Language
en
Open access
bronze
Funders
  • Lady Tata Memorial Trust
  • Louis-Jeantet Foundation
  • Fondazione Telethon
  • American Society of Hematology
  • Else Kröner-Fresenius-Stiftung
  • New York Stem Cell Foundation
  • Ministero della Salute (E-Rare-3, GR-2018-12366006, GR-2019-12369499)
  • Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN2017)
  • European Research Council
  • European Hematology Association

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.